Since biological therapeutics are derived from living organisms, their manufacture and validation presents difficulties not encountered during traditional small molecule drug development. Despite the ...

The global pandemic has increased focus and scrutiny on molecular diagnostic assay development, resulting in a need for assays that provide quick results while delivering expected performance and ...

High-throughput screening (HTS) is a cornerstone of modern drug discovery, enabling the evaluation of thousands to millions of potential drug compounds. Advances in automation and miniaturization have ...

A good bioassay, like a good marriage, joins two partners in a bond and is mutually beneficial. In the case of bioassays, optimal design and development and accurate statistical analysis comprise a ...

Molecular diagnostic assay development and design is no simple task, and several factors affect the performance and usability of a test. Diagnostic companies can enhance assay stability and ...

Optimizing PCR assays for assay development (AD) workflows typically involves a range of interdependent factors. These include thermocycling conditions, enzyme levels, buffer chemistry, and ...

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced a strategic partnership with PathAI, a leading provider of AI-powered research tools and services for ...

This article and associated images are based on a poster originally authored by Linda Kitching, Maxime Couturier, Jonathan Tart, Erik Elebring, Marcel Taillefer, Claudio Pathe, Giulia Bonetto, ...

Friends of Cancer Research initiated a research partnership, inviting HRD assay developers to participate in two blinded analyses. In the first, 11 assay developers reported HRD status for the Cancer ...